— Know what they know.
Not Investment Advice

WHWK NASDAQ

Whitehawk Therapeutics Inc
1W: +4.4% 1M: -11.4% 3M: -9.0% YTD: +36.5% 1Y: +38.2% 3Y: -18.6% 5Y: -87.5%
$3.33
+0.19 (+6.05%)
 
Weekly Expected Move ±8.3%
$3 $3 $3 $3 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 29 · $189.8M mcap · 24M float · 1.84% daily turnover · Short 56% of daily vol
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 14.08.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$189.8M
52W Range1.97-5.5
Volume290,060
Avg Volume434,665
Beta0.81
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEODavid J. Lennon
Employees32
SectorHealthcare
IndustryBiotechnology
IPO Date2017-08-01
2 Headquarters Plaza
Morristown, NJ 07960
US
551 321 2234
About Whitehawk Therapeutics Inc

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Recent Insider Trades

NameTypeSharesPriceDate
Lennon David James A-Award 193,957 $4.09 2026-09-15
Lennon David James A-Award 193,957 — 2026-09-15
Giacobello Scott M. A-Award 118,476 $4.09 2026-09-15
Giacobello Scott M. A-Award 118,476 — 2026-09-15
Dugan Margaret A-Award 81,250 $4.09 2026-09-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms